000087843 001__ 87843
000087843 005__ 20200716101600.0
000087843 0247_ $$2doi$$a10.3390/molecules24142570
000087843 0248_ $$2sideral$$a116270
000087843 037__ $$aART-2019-116270
000087843 041__ $$aeng
000087843 100__ $$0(orcid)0000-0002-1349-616X$$aSerrano-Sevilla, Inés
000087843 245__ $$aNatural Polysaccharides for siRNA Delivery: Nanocarriers Based on Chitosan, Hyaluronic Acid, and Their Derivatives
000087843 260__ $$c2019
000087843 5060_ $$aAccess copy available to the general public$$fUnrestricted
000087843 5203_ $$aNatural polysaccharides are frequently used in the design of drug delivery systems due to their biocompatibility, biodegradability, and low toxicity. Moreover, they are diverse in structure, size, and charge, and their chemical functional groups can be easily modified to match the needs of the final application and mode of administration. This review focuses on polysaccharidic nanocarriers based on chitosan and hyaluronic acid for small interfering RNA (siRNA) delivery, which are highly positively and negatively charged, respectively. The key properties, strengths, and drawbacks of each polysaccharide are discussed. In addition, their use as efficient nanodelivery systems for gene silencing applications is put into context using the most recent examples from the literature. The latest advances in this field illustrate effectively how chitosan and hyaluronic acid can be modified or associated with other molecules in order to overcome their limitations to produce optimized siRNA delivery systems with promising in vitro and in vivo results
000087843 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/FPI-BES-2015-071304$$9info:eu-repo/grantAgreement/ES/MEC/FPU014-06249$$9info:eu-repo/grantAgreement/ES/MINECO/SAF2014-54763-C2-2-R
000087843 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000087843 590__ $$a3.267$$b2019
000087843 591__ $$aCHEMISTRY, MULTIDISCIPLINARY$$b70 / 177 = 0.395$$c2019$$dQ2$$eT2
000087843 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b141 / 297 = 0.475$$c2019$$dQ2$$eT2
000087843 592__ $$a0.698$$b2019
000087843 593__ $$aPharmaceutical Science$$c2019$$dQ1
000087843 593__ $$aChemistry (miscellaneous)$$c2019$$dQ2
000087843 593__ $$aDrug Discovery$$c2019$$dQ2
000087843 593__ $$aPhysical and Theoretical Chemistry$$c2019$$dQ2
000087843 593__ $$aOrganic Chemistry$$c2019$$dQ2
000087843 593__ $$aAnalytical Chemistry$$c2019$$dQ2
000087843 593__ $$aMedicine (miscellaneous)$$c2019$$dQ2
000087843 593__ $$aMolecular Medicine$$c2019$$dQ3
000087843 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000087843 700__ $$0(orcid)0000-0001-9475-6367$$aArtiga, Álvaro
000087843 700__ $$aMitchell, G. Scott
000087843 700__ $$0(orcid)0000-0001-6995-4302$$aDe Matteis, Laura
000087843 700__ $$0(orcid)0000-0003-1081-8482$$ade la Fuente, M. Jesús
000087843 773__ $$g24, 14 (2019), 2570 [34 pp.]$$pMolecules$$tMolecules$$x1420-3049
000087843 8564_ $$s7639743$$uhttps://zaguan.unizar.es/record/87843/files/texto_completo.pdf$$yVersión publicada
000087843 8564_ $$s486211$$uhttps://zaguan.unizar.es/record/87843/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000087843 909CO $$ooai:zaguan.unizar.es:87843$$particulos$$pdriver
000087843 951__ $$a2020-07-16-09:52:25
000087843 980__ $$aARTICLE